TW200621286A - Defective influenza virus particles - Google Patents

Defective influenza virus particles

Info

Publication number
TW200621286A
TW200621286A TW094139113A TW94139113A TW200621286A TW 200621286 A TW200621286 A TW 200621286A TW 094139113 A TW094139113 A TW 094139113A TW 94139113 A TW94139113 A TW 94139113A TW 200621286 A TW200621286 A TW 200621286A
Authority
TW
Taiwan
Prior art keywords
influenza virus
provides
defective
nucleic acid
influenza
Prior art date
Application number
TW094139113A
Other languages
Chinese (zh)
Inventor
Emmie De Wit
Monique I J Spronken
Ron A M Fouchier
Albert D M E Osterhaus
Original Assignee
Solvay Pharm Bv
Univ Erasmus Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv, Univ Erasmus Medical Ct filed Critical Solvay Pharm Bv
Publication of TW200621286A publication Critical patent/TW200621286A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the field of influenza virus and the vaccination against flu. The invention provides a conditionally defective influenza virus particle having seven different influenza nucleic acid segments. The invention also provides a conditionally defective influenza virus particle lacking an influenza nucleic acid segment selected from the group of segments essentially encoding acidic polymerase (PA), the basic polymerase 1 (PB1) and the basic polymerase 2 (PB2). In particular, the invention provides defective influenza virus particles having seven different influenza nucleic acid segments and lacking an influenza nucleic acid segment essentially encoding acidic polymerase. Furthermore, the invention provides use of a composition comprising a defective influenza virus particle according to the invention for the production of a pharmaceutical composition directed at generating immunological protection against infection of a subject with an influenza virus, and provides a method for generating immunological protection against infection of a subject with an influenza virus comprising providing a subject in need thereof with a composition comprising such defective influenza virus particle.
TW094139113A 2004-11-11 2005-11-08 Defective influenza virus particles TW200621286A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105696 2004-11-11
EP05105708 2005-06-27

Publications (1)

Publication Number Publication Date
TW200621286A true TW200621286A (en) 2006-07-01

Family

ID=39869799

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094139113A TW200621286A (en) 2004-11-11 2005-11-08 Defective influenza virus particles

Country Status (3)

Country Link
CN (1) CN102586199A (en)
BR (1) BRPI0517742A (en)
TW (1) TW200621286A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201310031D0 (en) * 2013-06-05 2013-07-17 Pirbright Inst The Cell
WO2015063085A1 (en) * 2013-10-28 2015-05-07 Thomas Muster Novel influenza virus vector for virotherapy
WO2023138651A1 (en) * 2022-01-19 2023-07-27 Versitech Limited Rationally designed single-round infectious virus and methods of use thereof

Also Published As

Publication number Publication date
BRPI0517742A (en) 2008-10-21
CN102586199A (en) 2012-07-18

Similar Documents

Publication Publication Date Title
WO2006051069A3 (en) Defective influenza virus particles
EP2078083A4 (en) A novel canine influenza virus and vaccine therefore
MX342639B (en) High titer recombinant influenza viruses for vaccines and gene therapy.
MX2007007889A (en) Rescue of influenza virus.
WO2007118206A3 (en) Canine influenza virus
AU2009303758A8 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2008061243A3 (en) Respiratory syncytial virus-virus like particle (vlps)
WO2007048086A3 (en) Canine influenza virus and related compositions and methods of use
PT1085904E (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
ES2510940A2 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2008011636A3 (en) Targeted gene delivery for dendritic cell vaccination
WO2007047831A3 (en) Functional influenza virus like particles (vlps)
JP2009511080A5 (en)
UA94717C2 (en) Modified influenza virus for monitoring and improving vaccine efficiency
WO2007124479A3 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
CA2817005A1 (en) Rabies glycoprotein virus-like particles (vlps)
WO2007084435A8 (en) Methods for treating hepatitis c
WO2007124327A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
ATE516924T1 (en) SANDBLASTING PARTICLES
WO2010084398A3 (en) Mouth rinse compositions including chemically modified silica or silicate materials for sustained delivery to tooth surfaces
TW200621286A (en) Defective influenza virus particles
WO2004085682A3 (en) Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza
WO2012054907A3 (en) Novel hemagglutinin 5 (h5) proteins for the treatment and prevention of influenza infections
MY146926A (en) Split-core-particles for the presentation of foreign molecules, especially for vaccine applications, and method for their production
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b